Blog

Chemical maker Dow signs supply agreement for bio-plastic materials

Cam White | May 25, 2023

(Reuters) – U.S. chemical maker Dow Inc said on Thursday it had signed a long-term supply agreement with bio-conversion company New Energy Blue for plastic materials made from corn residue, in a bid to move towards renewable energy sources for production. “This collaboration can help redefine how we source raw materials for our products, allowing […]

Roche dumps antisense hep B drug after bagging rival asset

TFT-admin | January 30, 2020

Roche has dropped an antisense hepatitis B drug shortly after licensing a rival therapy from Dicerna Pharmaceuticals. RG6004 fell off Roche’s pipeline as part of a periodic cull that affected a handful of other experimental programs. 

Synthetic locked nucleic acid modified antisense oligonucleotide RG6004 moved into the clinic early in 2017, opening […]

More than half of clinical trials still hidden from public view: report

TFT-admin | January 30, 2020

A new report out of the U.K. has spotlighted the continuing opacity of clinical trial reporting, with nearly 60% of more than 4,200 studies not showing results within a year, as mandated by new rules in the U.S.

Researchers from the University of Oxford led by transparency […]

Racing Blueprint, Lilly drug gets priority review for RET hopeful

TFT-admin | January 29, 2020

The FDA has granted a priority review to Eli Lilly’s selpercatinib, setting the stage for a third-quarter decision on whether to approve the RET inhibitor. Lilly based its filing on a phase 1/2 trial that linked selpercatinib to objective response rates (ORRs) of over 50% in heavily pretreated…

Monitoring emerging coronaviruses with next-generation sequencing

TFT-admin | January 29, 2020

Coronaviruses can cause fatal respiratory illnesses, and they are the culprits behind several outbreaks, including the current one ravaging China. An international team of scientists is suggesting that next-generation sequencing (NGS) be used to track the 2019 […]

Pfizer cans early-stage trials for cancer, sickle cell targets

TFT-admin | January 28, 2020

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

A few years back, Pfizer pretty much canned its entire neuro pipeline, but today the ax isn’t quite so red with blood. There’s a load of trials with its Merck-partnered Bavencio cancer drug that have […]

Adrangi mounts short attack on ‘worthless’ drugs of Sanofi ally

TFT-admin | January 28, 2020

Sahm Adrangi’s Kerrisdale Capital has trained its sights on Principia Biopharma, arguing the pipeline of the Sanofi partner is “worthless.” The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical […]

GSK hands TB vaccine to Gates Foundation’s nonprofit biotech

TFT-admin | January 27, 2020

GlaxoSmithKline has licensed a tuberculosis vaccine to the Bill & Melinda Gates Medical Research Institute. The deal sets the stage for a push to build on recent phase 2b data and make the vaccine available in low-income countries where TB is prevalent.

The vaccine […]

« Previous PageNext Page »